Advertisement

---

REGENERON PHARMACEUTICALS, INC.

Regeneron to Report Second Quarter 2013 Financial and Operating Results and Host Conference Call and Webcast on August 6, 2013

[2013-07-02] -


Regeneron Announces First Recipients of Annual "Regeneron Prize for Creative Innovation"

[2013-06-27] - New National Prize Recognizes Talented Early-Career Scientists Poised to Make Important Contributions to Scientific Discovery


Regeneron and Bayer Report Positive Phase 3 Results for EYLEA® (aflibercept) Injection in Myopic Choroidal Neovascularization (mCNV)

[2013-06-06] -


Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine

[2013-05-21] - Phase 2a study of the IL-4R alpha inhibitor, dupilumab, demonstrated 87% reduction in risk of asthma exacerbations in moderate-to-severe asthma patients with elevated eosinophils


Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)

[2013-05-15] - Comprehensive SARIL-RA development program to include 2,600 patients in four Phase 3 and one open-label extension trials


Regeneron Announces Upcoming 2013 Investor Conference Presentations

[2013-05-08] -


Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers